Drug patents opposed in 2024
Drug patents opposed in 2024 at the European Patent Office (EPO)
| Patent Number | Patent Title | Company | Recent Opposition Date | Recent Opposition By | Activity Alert |
|---|---|---|---|---|---|
| EP4058148B1 | Dosing Regimen For Anti-Bcma Agents | NA |
15 Mar, 2024
|
STRAWMAN
| |
| EP3300743B1 | Methods Of Vaccine Administration | ZOETIS SERVICES |
13 Mar, 2024
|
BOEHRINGER INGELHEIM VETMEDICA
| |
| EP3463315B1 | Compositions And Methods Of Using Nintedanib For Treating Ocular Diseases With Abnormal Neovascularization | ADS THERAPEUTICS |
13 Mar, 2024
|
MARGARET DIXON
| |
| EP3110449B1 | Medical Use Of A Dpp-4 Inhibitor | BOEHRINGER INGELHEIM |
13 Mar, 2024
|
SANDOZ
(and 1 more)
| |
| EP2913327B1 | Methylene Blue And Its Medical Use | PROVEPHARM LIFE SOLUTIONS |
07 Mar, 2024
|
AERA
(and 1 more)
| |
| EP3810201B9 | Gip/Glp1 Agonist Compositions | ELI LILLY |
07 Mar, 2024
|
GALENICUM HEALTH SLU
(and 6 more)
| |
| EP3870213B1 | Stable Semaglutide Compositions And Uses Thereof | NOVO NORDISK |
07 Mar, 2024
|
GENERICS UK
| |
| EP3488857B9 | Compositions Of Glp-1 Peptides And Preparation Thereof | NOVO NORDISK |
07 Mar, 2024
(Expiration: Mar, 2033)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 4 more)
| |
| EP3525775B1 | Arginine And Its Use As A T Cell Modulator | INSTITUTE FOR RESEARCH IN BIOMEDICINE IRB |
07 Mar, 2024
(Expiration: Oct, 2037)
|
HAMPTON KNOWLES
(and 2 more)
| |
| EP2691157B1 | Isopentyl Esters For The Use In Cosmetic, Dermatological, Or Pharmaceutical Compositions | EVONIK OPERATIONS |
07 Mar, 2024
|
KRAUS & LEDERER PARTGMBB
| |
| EP3509559B8 | Injectable Gels Comprising Cross-Linked Hyaluronic Acid And Hydroxyapatite, And Methods Of Manufacturing Thereof | ALLERGAN PHARMACEUTICALS |
07 Mar, 2024
|
MERZ PHARMA
| |
| EP2283851B1 | Compositions And Methods For Promoting Hemostasis And Other Physiological Activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
06 Mar, 2024
|
EIP
| |
| EP3381438B1 | Composition For Injection Of Hyaluronic Acid, Containing Hyaluronic Acid Derivative And Dna Fraction, And Use Thereof | BMI KOREA |
06 Mar, 2024
|
MASTELLI
| |
| EP3090729B1 | Emulsion | VITUX GROUP |
06 Mar, 2024
|
SIRIO HEALTHCARE ANHUI
| |
| EP3291789B1 | Improved Color Depositing Shampoo | CELEB |
04 Mar, 2024
|
CLARIANT PRODUKTE DEUTSCHLAND
| |
| EP3466491B1 | Hair Treatment Method And Kit Thereof | WELLA OPERATIONS |
04 Mar, 2024
|
HENKEL
| |
| EP3619232B1 | Multikinase Inhibitors And Uses In Ocular Fibrosis | AIVIVA BIOPHARMA |
04 Mar, 2024
|
MARGARET DIXON
| |
| EP3345604B1 | Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations | H LUNDBECK |
01 Mar, 2024
|
ALFRED E TIEFENBACHER
(and 1 more)
| |
| EP3536712B1 | Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9) | REGENERON PHARMACEUTICALS |
29 Feb, 2024
|
AMGEN
| |
| EP3897608B1 | Dietary Butyrate For Treating Or Preventing An Allergic Disorder | SOCIT DES PRODUITS NESTL |
29 Feb, 2024
|
NUTRICIA
| |
| EP3860590B1 | Methods For The Treatment Of Scleroderma | ARENA PHARMACEUTICALS |
29 Feb, 2024
|
TEVA UK
(and 1 more)
| |
| EP2995315B1 | Compositions And Methods For Treating Hematologic Cancers Targeting The Sirp Alpha- Cd47 Interaction | UNIVERSITY HEALTH NETWORK |
22 Feb, 2024
|
LEEMING
| |
| EP3651730B1 | New Composition For Straightening Hair | DI VISCO |
20 Feb, 2024
|
HENKEL
| |
| EP3452175B1 | Gentle Cleansing Compositions With Makeup Removal Properties | LOREAL |
20 Feb, 2024
|
HENKEL
| |
| EP3666797B1 | Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) | AMGEN INC |
19 Feb, 2024
(Expiration: Aug, 2028)
|
REGENERON PHARMACEUTICALS
(and 1 more)
| |
| EP2687202B1 | Subcutaneous Anti-Her2 Antibody Formulation | F HOFFMANN LA ROCHE |
12 Feb, 2024
|
ACCORD HEALTHCARE
| |
| EP3485890B1 | Treatment Of Metabolic Disorders In Canine Animals | BOEHRINGER INGELHEIM VETMEDICA |
09 Feb, 2024
|
CEVA SANTE ANIMALE
| |
| EP2508188B1 | Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate | ASTRAZENECA |
09 Feb, 2024
|
KRAUS & LEDERER PARTGMBB
(and 4 more)
| |
| EP3263110B1 | Solid Preparation | TAKEDA PHARMACEUTICAL |
08 Feb, 2024
|
SANDOZ
| |
| EP3250681B1 | Compositions And Methods For T Cell Delivery Of Therapeutic Molecules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
05 Feb, 2024
|
JAMES POOLE
| |
| EP3883606B9 | Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody | JANSSEN BIOTECH INC |
05 Feb, 2024
(Expiration: Sep, 2039)
|
SAMSUNG BIOEPIS NL
(and 1 more)
| |
| EP3613421B1 | Dry Powder Inhaler And Methods Of Use | VECTURA |
02 Feb, 2024
|
GENERICS UK
| |
| EP3240842B1 | Novel Film Coating Composition | IDEAL CURES PVT |
01 Feb, 2024
|
KADOR & PARTNER PARTG MBB
| |
| EP4093367B1 | Isotropic Concentrate And Wash Compositions | UNILEVER |
30 Jan, 2024
|
HENKEL
| |
| EP4090310B1 | Hair Treatment Composition | UNILEVER |
26 Jan, 2024
|
DALLI WERKE
| |
| EP4023755B1 | Artificial Nucleic Acid Molecules For Improved Protein Expression | CUREVAC SE |
26 Jan, 2024
(Expiration: Dec, 2035)
|
SANOFI
(and 3 more)
| |
| EP4021929B1 | Ham15-52 Analogues With Improved Amylin Receptor (Hamy3R) Potency | GUBRA APS |
26 Jan, 2024
|
STRAWMAN
| |
| EP3368047B1 | Synthetic Composition And Method For Modulating Emotion And Mood Disorders | GLYCOM AS |
25 Jan, 2024
(Expiration: Oct, 2036)
|
WEICKMANN & WEICKMANN PARTMBB
| |
| EP3892295B1 | Individualized Vaccines For Cancer | TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH |
25 Jan, 2024
(Expiration: May, 2032)
|
WITHERS & ROGERS LLPJONES NICHOLASWRIGHT HOWARD WALLIN NICHOLAS
| |
| EP3697392B1 | Tablets Comprising Tamsulosin And Solifenacin | SYNTHON BV |
23 Jan, 2024
(Expiration: Oct, 2038)
|
ADALVO
| |
| EP3363811B1 | Method For Producing Fusion Protein Having Igg Fc Domain | ALTEOGEN INC |
18 Jan, 2024
(Expiration: Oct, 2036)
|
BOULT WADE TENNANT
(and 3 more)
| |
| EP3769781B1 | Stable Anti-Ifnar1 Formulation | ASTRAZENECA AB |
18 Jan, 2024
(Expiration: Aug, 2036)
|
MAIWALD
| |
| EP3233204B1 | Composition For Enhancing Hair Fiber Properties | PROCTER AND GAMBLE CO |
16 Jan, 2024
(Expiration: Dec, 2035)
|
HENKEL
| |
| EP2858496B9 | Oils With Anti-Inflammatory Activity Containing Natural Specialized Proresolving Mediators And Their Precursors | SOLUTEX NA LLC |
11 Jan, 2024
(Expiration: May, 2033)
|
EPAX NORWAY
| |
| EP3886820B8 | Capsule Formulations | CHEMOCENTRYX INC |
11 Jan, 2024
(Expiration: Nov, 2039)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 1 more)
| |
| EP3970513B1 | Non-Tobacco Oral Nicotine Pouch Composition | PHILIP MORRIS PRODUCTS SA |
11 Jan, 2024
(Expiration: Nov, 2040)
|
NICOVENTURES TRADING
| |
| EP3648796B1 | Dispersion For An Aqueous Spray Formulation With Controlled Mechanical Degradation | GREENA BV |
05 Jan, 2024
(Expiration: Jul, 2037)
|
STRAWMAN
| |
| EP3930670B1 | Biobased Pearlescent Waxes | BASF SE |
04 Jan, 2024
(Expiration: Feb, 2040)
|
EVONIK OPERATIONS
(and 1 more)
| |
| EP3618875B1 | Combination Therapy | NOVARTIS AG |
04 Jan, 2024
(Expiration: Apr, 2038)
|
STADA ARZNEIMITTEL
| |
| EP3724319B1 | Methods For Obtaining Muscle Derived Cells | INNOVACELL AG |
03 Jan, 2024
(Expiration: Dec, 2038)
|
OLIGSCHLGER
|